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Abstract
Background: Patient-centered care is pillar 1 of the “End TB” strategy, but little has been documented in the
literature about what this means for people living with rifampicin-resistant (RR-TB). Optimizing care for such
individuals requires a better understanding of the challenges they face and the support they need.
Methods: A qualitative study was done among persons living with RR-TB and members of their support network. A
purposive sample was selected from a larger study population and open-ended interviews were conducted using a
semi-standard interview guide. Interviews were recorded and transcribed and the content analyzed using an
iterative thematic analysis based in grounded theory.
Results: 16 participants were interviewed from three different provinces. Four distinct periods in which support was
needed were identified: 1) pre-diagnosis; 2) pre-treatment; 3) treatment; and 4) post-treatment. Challenges common
in all four periods included: socioeconomic issues, centralized care, and the need for better counseling at multiple
levels.
Conclusions: Beyond being a “very humiliating illness”, RR-TB robs people of their physical, social, economic,
psychological, and emotional well-being far beyond the period when treatment is being administered. Efforts to
tackle these issues are as important as new drugs and diagnostics in the fight against TB.
Keywords: South Africa, Costs, Challenges, Social support, Counseling
Introduction
The World Health Organization (WHO) has emphasized
the importance of “patient-centered care” in efforts to
End Tuberculosis (TB) [1]. Defined as “providing care
that is respectful of, and responsive to, individual patient
preferences, needs, and values, and ensuring that patient
values guide all clinical decisions,” patient-centered care
is important enough to form pillar one of the WHO’s
strategy to eliminate TB in the next decade [2]. While
advocates prefer the term “person-centered care” so that
an individual is not defined by his or her disease, [3] this
attention to the unique needs of people living with TB is
a welcome change in a field that has largely been domi-
nated by a de-humanizing public health approach [4].
Despite wide-spread use of the term there is only a
general definition of what person-centered care means.
The End TB strategy document, for example, describes
the following types of services that could be considered
elements of patient-centered care: health education; im-
proved communications (including using digital tech-
nologies); adherence support (including nutritional,
financial, and transportation); psychological support; de-
centralized services; and staff education [5]. There is
limited documentation, however, of the specific needs
and values of people living with TB, how these needs
change during their illness and what kind of support
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people living with TB receive to address their needs [6].
Nowhere is this more apparent than in the diagnosis and
treatment of rifampicin-resistant forms of TB (RR-TB), a
type of TB that causes almost 600,000 people to become
sick annually. [7]. Only a small percentage of people liv-
ing with RR-TB are diagnosed with the disease or started
on treatment [8] Those who are face an arduous treat-
ment journey involving months of therapy with highly
toxic agents that cure just over half of them [9, 10]. The
diagnosis and treatment of RR-TB is fraught with diffi-
culty, and some people living with RR-TB have described
the treatment as being worse than the disease [11].
In this context, what would constitute “patient-cen-
tered care”? Studies reveal multiple challenges faced by
people with RR-TB, including: economic struggles; food
insecurity; discrimination and stigma; depression and
anxiety; difficulty accessing therapy; hospital-based care;
and side effects from treatment [12–17]. Some studies
have documented that addressing these challenges by
providing nutritional supplementation, conditional cash
transfers, counseling, and peer support groups can result
in improved TB outcomes [18–21]. Yet little is known
about the specific support needs identified by people liv-
ing with RR-TB themselves and their caregivers in a
high-burden RR-TB context. We report a qualitative
study describing the meaning of ‘patient- or people-
centred care’ from the perspectives of people treated for
RR-TB in South Africa and their supporters, including
patients’ experiences accessing and receiving care for
RR-TB from the time f symptom development through
treatment completion.
Methods
Open-ended qualitative interviews were done with 16
participants between November, 2018 and March, 2019.
Eight were people treated for RR-TB and eight were per-
sons who provided support to individuals during RR-TB
treatment.
This qualitative study was part of a larger health sys-
tems study led by the University of Cape Town assessing
implementation of, and access to, decentralized treat-
ment for RR-TB in South Africa. [22] The goal of this
larger study was to describe patient pathways through
different levels and healthcare facilities in order to
visualize the extent to which RR-TB treatment was
decentralized across different geographic and health sys-
tem settings. This study took place in three South Afri-
can provinces: 1) Eastern Cape, which has a largely rural
population and limited resources; 2) KwaZulu-Natal,
which has high rates of both RR-TB and HIV and a large
urban population; and 3) Western Cape, which has a
mix of urban and rural populations, a lower rate of HIV
co-infection than the other provinces, and more access
to health care resources.
The sample for this qualitative study was selected pur-
posively from this larger study population to ensure rep-
resentation of at least two individuals from the following
categories: 1) urban versus rural; 2) varied socioeco-
nomic status (as indicted by pre-diagnosis employment)
and 3) use of newer TB drugs in their treatment regi-
mens. Support persons were identified by the original
participant, except for the support people of two partici-
pants who had died. In these instances, clinic staff were
asked to identify key support people.
A semi-structured interview guide (see Additional file 1)
was used to ask about challenges with RR-TB diagnosis
and care, sources of support during care, treatment prefer-
ences, suggestions for improving care, and any additional
comments or concerns of their treatment experience.
Given the changing landscape of RR-TB treatment, more
structured questions were asked about treatment prefer-
ences, including whether a person preferred all-oral ther-
apy and shorter therapy duration, and how these
preferences would change if the chance of cure differed
with the options offered. Interviews were carried out by
two interviewers (SH, ML) in the preferred language of
the participant (isiZulu, isiXhosa, Afrikaans or English,
with translation if needed) and recorded. All recordings
were transcribed directly into English. Transcripts were
coded, entered manually into Microsoft Excel and ana-
lyzed to generate themes, assess content and identify pat-
terns. A total of 16 participants were interviewed: 12
included pairs of patients and supporters; two were sup-
porters of patients who died; and two were patients who
declined to name a supporter to be interviewed.
A thematic network analysis was used to analyze the
data from the transcripts (Fig. 1) [23, 24]. The analysis
was iterative in that: interviews were transcribed imme-
diately after the interview, transcripts were reviewed by
the team, and the interview guide updated to reflect new
information (i.e. a participant mentioned a positive result
from having RR-TB was that he stopped smoking, so
participants in subsequent interviewers were then specif-
ically asked about positive aspects of having RR-TB).
After an initial review of the data, a coding system was
developed by one study team member (JF), verified/
modified by another (ML), and the first 16 interviews
were analyzed. Discrepancies were resolved via discus-
sion and there was agreement among all study team
members on the final analytic framework used. Inter-
views were halted after the initial 16 participants since
inductive thematic saturation had been reached (deter-
mined by two team members, JF and ML), [25] as no
new codes or themes were emerging in the dataset [26].
Ethics
This study was approved by the Human Research Ethics
Committee at the University of Cape Town (350/2016).
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The study was explained to all participants and written
consent for participation and recording was obtained.
Terminology
The term “patient” describes the person who was treated
for RR-TB. The term “supporter” describes the person
or persons who were identified by the patient as their
key source of support. The term “participant” includes
both patients and supporters.
Results
Sixteen interviews were conducted pertaining to the care
and treatment of 10 patients (Table 1). Eight patients
were interviewed and they came from urban settings
(N = 4), rural settings (N = 3) and a correctional facility
Fig. 1 Thematic network analysis of Patient –Centered Care
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1 1 F 36 Urban No 0
2 1 M 30 Urban Yes 1 F
3 1 M 36 Rural Yes 1 F
4 1 M 22 Urban Yes 0
5 1 M 53 Rural Yes 1 F
6 0 F 36 1 F
7 1 M 48 Correctional Facility No 0
8 1 F 24 Urban Yes 3 2 M, 1 F
9 1 M 29 0
10 0 F 27 Rural Yes 1 F
Total interviews 8 8
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(N = 1). Two of the patients were unemployed and six
were employed prior to being diagnosed with RR-TB.
Two of the patients received the new drug bedaquiline
during treatment. In order to ensure that the experience
of patients who had unsuccessful outcomes were docu-
mented, two supporters of patients who died were also
included. Four distinct time periods were identified by
patients and supporters in which they faced unique chal-
lenges requiring support. Each of these is described in
detail below, including the key activities that had to be
accomplished, challenges faced by the patient and his or
her supporters, and supporting factors throughout each
period of treatment (Table 2).
Pre-diagnosis period (usually lasting several weeks to
months)
The hallmark of the pre-diagnosis period was that the
patient was physically sick but did not know the under-
lying cause of their symptoms. Key tasks which had to
be accomplished were managing symptoms and finding
out the diagnosis, whilst they continued to provide fi-
nancially for their families or played another key family
role (such as child care).
All patients reported feeling physically sick and visiting
at least two healthcare facilities prior to their RR-TB diag-
nosis. Some were initially told they did not have TB. Dur-
ing this period, some patients had to leave their place of
residence and move back home to be with family mem-
bers who could provide physical care or help with hous-
ing, money, food, and/or child care. All six of the eight
patients who were working when they developed symp-
toms altered their jobs or duties which led to a reduced
income. This economic loss was compounded by incur-
ring additional expenses whilst trying to obtain a diagno-
sis. Two patients reported providing care for other family
members who had RR-TB, a largely negative experience:
“It could be that I got [RR-TB] from my family
member because I was the one that was taking care of
her … I was the one to transport her with a wheel
barrow to the ambulance.” (male, age 30)
Only a few patients had support during this period. This
was usually from family members/spouses (almost always
females) and included encouragement, emotional support,
childcare, and in some cases, monetary support. Sup-
porters identified at this time remained the main support
people throughout the four periods identified in the study.
Pre-treatment period (usually lasting several days to
weeks)
The pre-treatment period was a time of great uncer-
tainty for patients and supporters. Key tasks during this
time were: processing their RR-TB diagnosis; disclosing
their RR-TB status to others and encouraging them to
be checked for RR-TB; obtaining both general informa-
tion about RR-TB as well as the immediate next steps
for treatment; getting to a treatment center to start
treatment; and managing the loss of normal roles and
social identities.
In terms of disclosure of the diagnosis, most patients
felt this was done in a sympathetic way either in person
or telephonically by the nurse at the diagnosing clinic.
However, some participants felt the nurses did not have
adequate information to share with them and others did
not have a positive experience.
“ … they did not explain very clearly what was
happening. I had the paper with me and then they
called me to check the paper. They then said come
here and put a mask on me. They told me to sit
outside and wait there. They did not treat me well.”
(male, age 30).
Others reported that the nurses interacted in a kind
manner, but their messages contained information
meant to evoke fear, using terms like “most dangerous”
to describe RR-TB and emphasizing what would happen
to the patients if they did not take their treatment.
“She was very friendly. She had a poster that she
showed me about the consequences of not taking my
treatment” (male, age 29).
One of the most stressful patient tasks was disclosing
their diagnosis to family members while at the same time
encouraging family members to get tested for TB. This
task evoked a great deal of guilt and stress for which little
support was provided by the healthcare system.
“ She even told me that I have to tell them at home to
come and check because maybe I might have spread it
at home.” (male, age 30)
The task of sharing their diagnosis with family mem-
bers while also telling them that they may have been in-
fected led to feelings of guilt and shame among almost
all patients, and resulted in discrimination from family
members. Some reported losing support they had re-
ceived during the pre-diagnosis period and some were
made scapegoats for other family problems, including
one family that blamed the patient’s disclosure as the
reason his nephew failed to pass his school exams.
Another significant task for patients and their sup-
porters during the pre-treatment period was being ad-
mitted to the treating hospital for initiation of therapy.
All treatment initiation sites were located outside of the
patient’s home community. Patients and supporters
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Table 2 Challenges and Supporting Factors which Emerged in the Four Phases of RR-TB Treatment
Pre-diagnosis: Patient
was symptomatic but
had not yet been
diagnosed with RR-TB
Pre-treatment: Patient had
been diagnosed with RR-TB
but had not yet been started
on treatment
Treatment: Patient was prescribed
and/or taking treatment for his or
her RR-TB
Post-treatment: RR-TB treatment
was complete but the patient
was still managing conse
quences of having survived RR-TB.
Challenges







activities of daily living
Adverse events experienced by all
patients. These varied from those
that impacted significantly on
patients’ lives to being tolerable.





Pill burden difficult to tolerate
Patients weak and inadequate
physical support from hospital
staff to bath etc.
Adverse events not always
addressed in a timely fashion
Health system
challenges
Long waiting times and










After discharge from hospital, due
to poor communication there was
inadequate care at outpatient
facilities.
Inadequate information on
adverse events and possible
permanent disabilities
Multiple visits prior to
diagnosis
Accessing RR-TB services
necessitates long distance travel.
RR-TB patients stigmatised, so
that travel is discriminatory and
frightening
Shorter regimen preferable, but
longer regimen preferable if




Loss of income from
not working. Additional
expenditure of the cost
of transport to
health facilities
Due to permanent disability
unable to continue working -
severe economic impact on the
household
Confusion regarding access to





Receiving news of diagnosis
and the implications of this
diagnosis
Loss of identity Sense of loss and anger with
permanent disability. No longer
the same person
Anxiety and concern about
infecting others




Unable to continue with
household responsibilities
eg. child-minding, cleaning
Disclosure – implications and
fear of stigma and
discrimination
Hospitalisation – someone else
needed to take over family and
household responsibilities
Inadequate community
awareness and understanding of
TB and its transmission
Stigma affected whole family,
including at work
Social isolation during
hospitalisation due to transport
costs for family to visit patient
Some sources of support






Masks – a visual sign of stigma
and discrimination
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uniformly described transportation challenges. In one
extreme case, reported by a supporter, the patient was
told he needed to be admitted to his region’s RR-TB
hospital, located far from the diagnosing clinic, and
instructed to wait for an ambulance to take him there.
The ambulance arrived at midnight.
“When the ambulance came, the ambulance driver
said that he was knocking-off and he was not going to
[the regional RR-TB hospital] so that is when he took
the patient to [the tertiary hospital an hour and a half
away].” (female supporter of female patient age 36 at
time of death).
Transport challenges led to some patients realizing the
implications of their disease.
“There were three of us in this ambulance but they
told me to sit in the far corner of the ambulance. I said
to myself this means that I am dead.” (male, age 36).
In the RR-TB treatment facility, however, many felt
they were provided with more information and felt more
welcome. Information was almost always provided by
nurses at the receiving hospital.
“As I arrived the nurses came outside and met me and
they asked me what was the matter. I said I was sick
and they told me that I was not sick. I noticed as I
entered the ward that there were other sick people there
and I didn’t seem that sick. The male nurse told me that
this was going to be my home for the next three to four
months” (male, 36 years)
All the participants reported socioeconomic struggles
during this pre-treatment period, both in terms of lost
work and normal activities that had to be taken over by
others.
Almost all socioeconomic, emotional/psychological,
and social support provided was from family members
and almost always from females. Of note, supporters
also reported that they themselves needed emotional/
psychological help as well.
Treatment period (usually lasting 12 to 36months)
The treatment period is often the time in the therapeutic
journey of a person living with RR-TB that receives the
most attention—likely because it lasts for the longest
duration. Key challenges negotiated by patients during
this period were: initiating treatment; dealing with ad-
verse events; adhering to treatment; moving from the
hospital back to their home communities; and managing
the prolonged loss of their normal roles and identities.
Most of the participants felt the hospitals had provided
good care, although there were some notable exceptions.
Again, nurses were identified as the primary sources of
information and support.
Table 2 Challenges and Supporting Factors which Emerged in the Four Phases of RR-TB Treatment (Continued)
Pre-diagnosis: Patient
was symptomatic but
had not yet been
diagnosed with RR-TB
Pre-treatment: Patient had
been diagnosed with RR-TB
but had not yet been started
on treatment
Treatment: Patient was prescribed
and/or taking treatment for his or
her RR-TB
Post-treatment: RR-TB treatment
was complete but the patient
was still managing conse




of a family member who
had had RR-TB
Importance of nurses: Main
providers of information, care
and support
Nurses identified as the most
important source of support and
information both in hospital and
after discharge




Religious faith and the support of
religious leaders important for
some patients.
Physical support with






ing facilities took time
Emotional support and
encouragement by
family member to keep
going to health facilities
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“ … they were always coming on time when it was
time for me to take my pills, they would even help me
to take pills, I would also notice that if ever I was not
feeling well, they would notice and they would ask me
what is it that is making me feel down. They took good
care of me but not all of them because people are not
the same.” (male, age 22).
However, not all patients felt support from the nurses.
One patient who experienced multiple side effects and
had a difficult treatment journey noted:
“Yes, the nurses would just be there to get paid. They
are just doing their work and working to get paid …
There is no love in the hospital. The sisters and the
nurses there, they tell you straight if you don't take
your pills you will die.” (male age 53)
Distance to the hospital made it hard for supporters to
visit, as did the practice of not allowing family to visit
patients on the wards. Deprived of their usual social sup-
port, patients identified new sources of assistance in-
cluding other patients hospitalized for RR-TB treatment,
cleaning staff, religious leaders, family members of other
patients who were visiting, and prison wardens. This as-
sistance varied from physical support with washing/eat-
ing, educational support, to emotional support.
“ … I met a cleaning lady that told me that the only
thing that you shouldn't do in that hospital is to get
sick to the point where you lay in bed and you can't do
anything for yourself because then you are going to
die.” (female, age 24)
“The guy [s] always gave [me] hope saying that one
day we will be out of this place, we came here in wheel
chairs.” (male, age 30)
“ … the pastor also feeds them; the reason is that
sometimes we come to visit a church member but
when we are here, we don’t choose. We help everyone.”
(female supporter of male)
On discharge from hospital patients had to re-establish
support networks within the community, which was chal-
lenging at times. Sometimes male family members provided
short-term assistance with material needs, including the
provision of housing or money. Again, nurses were identi-
fied as a primary source of support during this transition
period. Much of this had to do with the direct physical care
they provided during ongoing outpatient treatment.
“The person giving the injection was kind and worked
fast- they didn’t want me to wait long. At the end
when I was gaining weight he told me that I would get
better if I complete the treatment” (female, age 36)
Every patient who participated in the study experi-
enced adverse events. Some of these were mild and tol-
erable, whereas others had a significant impact on the
life of the patient. Injection site pain and hearing loss
were described by many patients as were nausea, vomit-
ing and loss of appetite. Two patients reported memory
loss and bad dreams. Two male patients reported impo-
tency which was troubling to them. On discharge, one
patient developed hallucinations, ran away from home
and was found in a psychotic state. As his wife reported:
“He ran into the bush... He was found on the third day
at night. He was trying to cross the road but he was
just covered with a blanket. He was naked. He had a
wound on his arm so we don't know whether he fell
down or whether he was hit by a car or what
happened.” (female, supporter of male patient age 53).
One participant reported that the treatment caused
more problems for her than the RR-TB:
“You have to take all 30 pills and finish. For me, I felt
that I was not sick. I literally got sick when I started
taking the pills.” (female, age 24).
Patients reported that they adhered to treatment des-
pite the many challenges, largely because they feared
dying or infecting others. Many reported witnessing
other patients in the hospital die and did not want that
to happen to them.
“There was a lot who died in front of me for not taking
their pills.” (male, age 22).
In terms of treatment preferences, several patients
identified the injectable as one of the more challenging
medications. However, the high pill burden was men-
tioned as equally challenging by others. As the supporter
of a patient who died said:
“I think it was the pills. It was a lot of pills. It was
maybe more than eighteen pills. It was too much.”
(female supporter of female who died at age 27).
When asked if they would prefer a shorter (9 month)
regimen or a longer (24 months) regimen, participants
uniformly replied that they would prefer a shorter regi-
men. However, when asked for their preference if the
shorter regimen did not cure as many patients as the
longer one, most participants stated they preferred a
longer regimen with a higher chance of cure:
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“I will go for two years. What if I am the one that will
not be healed? No way!” (male age 36 years).
While most patients stated they would prefer an
injectable-free regimen, some said they would have the
injectable if this reduced the pill-burden:
“I would take the pills and the injections but only if
the pills are less.” (female, age 24)
Participants continued to experience stigma and dis-
crimination, which had a major impact on their social
identities:
“It was actually very humiliating for me because you
have to sit with a mask on your face at the clinic and
people are looking at you and nobody wants to come
near to you. I heard someone by the clinic saying if
they are walking around like that,[you] have
dangerous viruses and things … It is a very
humiliating illness.” (female age 24).
All patients lost the ability to contribute economically
during treatment, and many had to have assistance with
their normal social roles, for example as mother. Some
of the patients received a disability grant—and men-
tioned that social workers were a great source of sup-
port. Two patients, however, were told they could not
apply for a disability grant as they did not qualify and
one patient was told he would face legal consequences
and “be arrested” if he applied, as the social worker felt
he could still work. One patient reported receiving one
food package from the Red Cross, but no other sources
of nutritional support were described.
Post-treatment period (ongoing)
This period was defined as the time when RR-TB treat-
ment was completed but when patients were still wrest-
ling with the impact of RR-TB in their lives. Key tasks
were: managing permanent side effects; re-integrating
back into society/roles; managing concerns about recur-
rent RR-TB disease; and managing overall health.
Four of the patients who were treated for RR-TB de-
veloped permanent disabilities as a result of their treat-
ment, usually injectable-related hearing loss. These
patients and their families felt a profound sense of loss
and anger:
“These nurses didn’t even explain to me about the
injection. I discovered it when I was there, I must also
get an injection. They never even told me that my ears
would be closed and they never told me that maybe I
will end up no longer being the person that I used to
be.” (male, age 53).
Some participants did describe longer-term benefits
from their RR-TB diagnosis. Two reported they had
stopped smoking during treatment, one that he had
stopped drinking alcohol during treatment and one re-
ported a sense of thankfulness:
“It did change some things. I stopped smoking … I
somehow had no choice because I could not mix
cigarettes with my treatment” (male, age 30)
All participants were asked what could be done to im-
prove the RR-TB services. Many recommended facility-
based changes to reduce waiting times at facilities,
shorten queues, and/or provide more support with daily
activities to weak hospitalized patients. One participant
specifically mentioned the need for more support staff to
feed and bathe patients too weak to do so themselves.
Others mentioned changing treatment regimens to make
them easier to take by reducing the daily pill-burden and
the side effects.
Participants were clear about what they would tell
other people suffering from RR-TB. Most stated they
would emphasize the importance of “following all the
rules” and “taking all the medicines.”
Of note, no new sources of support were recruited or
acquired during the post-treatment period by patients.
However, some of the participants reported feeling more
closely linked with their supporters. In one illustrative
example, one of the cured patients got the phrase “Stay
Strong” tattooed on her body. Her father was also going
to get the same thing tattooed on his arm in solidarity.
“I want to tell the story why I have ‘Stay Strong’
written on my body.” (male supporter of female
patient, age 24).
Discussion
This qualitative study identified numerous challenges
faced by people living with RR-TB that occurred in four
distinct time periods. While many of these challenges
were unique to some patients and supporters, others
were cross cutting, including socioeconomic issues;
problems due to centralized care; the need for better
counseling for patients and supporters; and more inter-
action with clinical staff. While some of these challenges
are hinted at in larger and more general concepts of
“person-centered care”, [27] our findings show many of
them are not addressed by National TB Programs
(NTPs) or existing health systems.
The interviews highlighted constant economic chal-
lenges from the time symptoms developed through the
post-treatment period, usually caused by lost work, new
expenses (especially travel and transport) and the need to
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recruit additional help to take care of tasks normally done
by the patient (e.g., childcare, household chores) These
findings reinforce previous studies highlighting the “cata-
strophic” costs associated with TB and RR-TB treatment,
even when such treatment is provided free of charge [28],
[29]. These socioeconomic challenges highlight the need
not only for social protection strategies to mitigate the
cost of illness and to prevent individuals with TB from be-
ing forced further into poverty, but also for direct socio-
economic support to enhance the chances of treatment
success. [30] In South Africa, although all patients with
RR-TB are eligible for disability grants for the duration of
treatment, [31] not all were advised to apply and assisted
with their applications. These data suggest that skilled so-
cial workers have a major role to play in the treatment of
RR-TB. However, previous studies have suggested that ac-
cess to such grants is often delayed and does not provide
economic support in the crucial first few months of treat-
ment. [32] Incorporating social protection strategies dir-
ectly into NTPs may help to eliminate catastrophic costs,
but it is unlikely that this will be accomplished by the tar-
get date of 2020. [33] Social protection should be a central
component of a person-centered approach to care. In fact,
studies have found that economic support linked with
counseling improves treatment adherence and the chance
of cure. [34]
The results also highlight the numerous challenges that
result from centralized treatment services. Patients treated
within decentralized models of care have treatment out-
comes that are similar compared with centralized care,
and health systems costs are lower with decentralized ser-
vices [35–37]. Implementation of decentralized care, how-
ever, has been limited by concerns around the provision
of “specialized” treatment in decentralized settings. This
study shows that even though many participants reported
positive in-hospital experiences, centralized care was often
not person-centered. People living with RR-TB were re-
moved from their existing sources of support and found
the transfers in and out of communities to be times of
greatest stigma and discrimination. Furthermore, the eco-
nomic burden on patients and households during
hospitalization was significant due to the loss of income
and the extra transportation expenses incurred.
Finally, this study showed that there is a dire need for im-
proved education and counseling for patients, their sup-
porters, and the health care staff who provide care. In
terms of health care staff, nurses were mentioned by all pa-
tients as the most significant sources of support. As such,
nursing staff appear to be the focal points for delivering
person-centered care. This crucial role must be recognized,
professionalized and supported by other members of the
health care team. Nurses at all levels should be provided
with more in-depth training on RR-TB treatment, helping
patients manage disclosure, how to minimize stigma and
discrimination, and how to help patients transition through
the different phases described in this paper. Reinforcement
of more positive and hopeful messaging should also be em-
phasized. Ancillary staff were also reported as sources of in-
formation and support. NTPs should consider more formal
training for, recognition of, and utilization of these individ-
uals with appropriate compensation. Some examples where
ancillary staff could be utilized include peer support groups,
peer networks, and inclusion of these individuals as “TB
champions”. Of note, the only role mentioned for doctors
by most participants was deciding about the initial treat-
ment regimen.
People living with RR-TB need more counseling and
support from the health care system. One area that
needs to be urgently addressed is disclosure counseling
(especially to family members)—which should be built
into contact tracing programs. In addition, in the post-
treatment period, after being discharged as ‘successfully
treated’, people still had significant medical needs. Some
of these could potentially be managed through improved
primary care services provided as part of universal health
care. [38] Many participants described the donning of a
mask as an activity that was associated with shame and
stigma. While the risk of transmission may be significant
in the pre-diagnosis, pre-treatment and very early treat-
ment periods, risk likely declines rapidly with effective
treatment. [39] Hence, it is important that evidence-
based (and not fear-based) infection control be practiced
throughout the lengthy treatment. For example, more
universal mask wearing within the health care system,
could help decrease both stigma and TB transmission.
[40] There have been some positive experiences in parts
of South Africa where primary care clinic attendees all
wear paper masks as part of administrative infection
control measures. [41]
Informed decision-making is one of the tenets of
patient-centered care. [42] When asked about treatment
preferences patients reported preferring shorter and
injectable-free regimens, but they leaned toward regi-
mens with the highest rate of cure. In addition, several
also noted that the pill burden and side effects were
challenging and they might be willing to take an injec-
tion if it meant fewer pills. While most patients in this
study indicated they would defer to the doctor for treat-
ment decisions, they did want to be informed about the
risks and benefits of treatment and have their prefer-
ences considered and discussed when deciding on the
therapeutic approach. This is rarely done in the care of
people with RR-TB and must be a central component of
RR-TB treatment moving forward. [43]
In terms of patient supporters outside of the health sys-
tem female family members provided almost all support
given to patients. As such, these women are vulnerable to
worsening poverty, [44] and becoming sick from RR-TB
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themselves. [45] Their needs should also be addressed as a
core part of patient-centered care. It was also notable that
the support person in the pre-diagnosis period usually
remained as core support throughout the treatment jour-
ney. These findings suggest that NTPs should identify key
patient supporters early in the diagnostic and treatment
process, provide counseling, education and, if possible,
support to these family members, and find ways to involve
them in all aspects of treatment.
There are several limitations to this study. First, the
sample is small, and although purposive sampling was
done, these findings may not be generalized to other
populations. Second, participants were all asked about
their treatment experiences retrospectively, and it may
be more beneficial to follow people throughout the
treatment journey and document their experiences pro-
spectively. Finally, although we interviewed the sup-
porters of two patients who had died, and one patient
who initially was unable to adhere to treatment, the
remaining patients were successfully treated. Individuals
with poor treatment outcomes including those who do
not complete the full course of treatment may provide
different perspectives.
Conclusion
In spite of these limitations, the study has important rami-
fications for TB policy and practice. Many in the larger
TB community have embraced the concept of “patient-
centered care” but few efforts have been made to imple-
ment such services. If this term is to move beyond popular
cosmetic use—which it must if we are serious about elim-
inating TB—more work is needed to ensure that the
unique challenges faced by each individual with RR-TB
and their support networks are addressed. There also
needs to be accountability when such needs are not met.
The way the global community responds to the failure to
eliminate TB-associated catastrophic patient costs will in-
dicate how serious we are about putting substance behind
this popular slogan. As this study has shown, beyond be-
ing a “very humiliating illness,” RR-TB robs people of their
physical, social, economic, psychological, and emotional
well-being far beyond the period when treatment is being
administered. Efforts to tackle these issues are as import-
ant as new drugs and diagnostics in the fight against TB.
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